Skip to content

BOTALYS

Active Public limited companyfounded 2011active for 15 yearsAvenue des Artisans 8, 7822 AthKBO/BCE: BE 0834.134.177 #3 company by equity in Ath, Professional and technical services sector

Lifetime

14 annual accounts with figures on one time axis
peak of €287,503 in 2019
€55,321▲ 70.5%
lowest -€3.1m in 2023
-€2.9m▼ €287,002
peak of €6.8m in 2023
€4.9m▲ 16.8%
€2.5m▼ 57.7%
peak of 24 FTE in 2024
16.8 FTE▼ 30.0%
Board9 names since 2013
9 directors and 8 others
Owners4 names in the annual accounts
15.55% and 2 others
Documentsfilings and deeds
30-06-202631 days before the deadline
2025abbreviated format
Gross margin from €32,440 to €55,321Loss of €2.9mStaff from 24 FTE to 16.8 FTE resigns as director 26-11Capital increase · Amendment of the articles 21-11Capital increase · Amendment of the articles 11-09

Key points

from the 2025 annual accounts

Losses

-€17.4m in 13 years
20132015201720192021-3.12023-2.92025

Every financial year from 2013 to 2025 closed with a loss. 2023 was the heaviest.

Turnover

≈ €160,000 estimated

The accounts state no turnover.

Staff

16 employees on 31-12-2025
6420216220221042023492024392025

In 2025, 3 employees joined and 9 left.

Liquidity

1.95 was 4.42 in 2024

Short-term debts rose from €1.1m to €1.1m.

Filings

14 annual accounts since 2012
AprilJune31 JulyOctober201520202025

Four of the last ten came late. The 2024 accounts came in latest, 33 days after the end of the period.

Position in the sector

-€2.9m

Lower net result than 91% of companies in research and development. The sector median is €454, over 344 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 375 companies had the same profile as BOTALYS has now. Each dot is one company, two years later.

91.7%
were still trading
7.2%
stopped another way
1.1%
went bankrupt
  • Small
  • 10 to 20 years old
  • solvency 30% or more
  • a loss of 10% of the balance sheet or more
Test of the method

The method was tested on the 497,894 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 375 companies, not a prediction for BOTALYS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Managing director,
Director,
Director, , since 31-05-2024
Director,
Director,
Director, , since 16-06-2025
and 3 others
  • 15.55%score equity €4.98bn (2025) · annual accounts 2025 of
  • 7.92%score equity €7.7m (2025) · annual accounts 2025 of

Shares in 1 company,

Board & ownership

Recent changes

resigns as director General meeting of 09-05-2025 · Gazette deed
Capital increase · Amendment of the articles The capital rose from €6,954,703.31 to €9,894,927.47, with 422,446 new shares · The capital fell from €9,894,927.47 to €4,179,541.13 · Contribution of €2,940,224.16 · General meeting of 12-11-2025 · Gazette deed
Capital increase · Amendment of the articles The capital rose from €5,992,851.35 to €6,234,975.63, with 51,958 new shares · The capital rose from €6,234,975.63 to €6,439,433.13, with 43,875 new shares · The capital rose from €6,439,433.13 to €6,861,307.59, with 90,531 new shares · General meeting of 27-08-2025 · Gazette deed
3 directors appointed, 2 reappointments, 1 statutory auditor reappointed , and (statutory auditor) reappointed · , (independent director) and appointed · acts as permanent representative · General meeting of 16-06-2025 · Gazette deed
All 48 events

Comparable companies

same main activity, similar in size and age
Company
BOTALYS Ath €7.4m €0.06m 66.4% 16.8
ImmunXperts Charleroi €9.6m €0.4m -16.7% 26.7
Perseus Biomics Leuven €5.2m €0.3m 39.2% 14.3
AQUATIC SCIENCE Verviers €3.8m €0.2m 85.2% 11
IPRATECH Charleroi €4.3m €1.5m 36.5% 15.6
TOKU-E EU Ghent €4.2m €1.0m 2.0% 11.8
BIO-SOURCING Liège €6.6m €1.6m 13.6% 17.3

These companies have the same main activity as BOTALYS: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €3.8m and €9.6m, founded between 2003 and 2016.

Official details

Source: KBO
Status
Active since 01-03-2011Normal situation
Activity
Research and development on biotechnologyNACE 72101and 2 others
Joint committee
220White-collar workers in the food industry · annual accounts 2025
Establishment unit
2.300.632.3407822 Ath, registered on 01-01-2020
Financial year end
31 December
Peppol
Reachable via Peppol
Company details

Annual accounts 2025

€7.4m▼ 26.6%
Employeeson 31-12-2025
16▼ 27.3%
Filing
Filed on 30-06-2026, 31 days before the end of the filing period
Financials

Insights on BOTALYS

BOTALYS files the abbreviated format. That format states no turnover. The gross margin rose from €9,081 in 2012 to €55,321 in 2025.

In July 2024, three directors stepped down. In October 2022, the Official Gazette published the appointment of as managing director.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about BOTALYS

What is the company number of BOTALYS?
The company number of BOTALYS is 0834.134.177. The VAT number is the same number with BE in front: BE 0834.134.177.
Where is BOTALYS based?
The registered office is at Avenue des Artisans 8, 7822 Ath.Company details
What does BOTALYS do?
According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
What is the legal form of BOTALYS?
BOTALYS is a public limited company (NV).
When was BOTALYS founded?
BOTALYS was founded on 01-03-2011.
Is BOTALYS still active?
Yes, BOTALYS is an active enterprise in the KBO register.
How many employees does BOTALYS have?
BOTALYS had an average of 16.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does BOTALYS fall under?
In its 2025 annual accounts, BOTALYS states joint committee 220 (White-collar workers in the food industry).
What is the turnover of BOTALYS?
The turnover in financial year 2025 is about €160,000. This figure is estimated from the gross margin of €55,321 and 992 comparable companies of the same size. It probably lies between €95,000 and €320,000. It is a rough estimate.
Is BOTALYS profitable?
In financial year 2025, BOTALYS made a loss of €2.9m.
Where can I find the annual accounts of BOTALYS?
BOTALYS filed 14 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of BOTALYS due?
BOTALYS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.